|
1
|
Wiles N, Thomas L, Abel A, Barnes M,
Carroll F, Ridgway N, Sherlock S, Turner N, Button K, Odondi L, et
al: Clinical effectiveness and cost-effectiveness of cognitive
behavioural therapy as an adjunct to pharmacotherapy for
treatment-resistant depression in primary care: The CoBalT
randomised controlled trial. Health Technol Assess. 18:1–167,
vii-viii. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Swaab DF, Fliers E, Hoogendijk WJ, Veltman
DJ and Zhou JN: Interaction of prefrontal cortical and hypothalamic
systems in the pathogenesis of depression. Prog Brain Res.
126:369–396. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Waarde JA, Scholte HS, van Oudheusden
LJ, Verwey B, Denys D and van Wingen GA: A functional MRI marker
may predict the outcome of electroconvulsive therapy in severe and
treatment-resistant depression. Mol Psychiatry. 20:609–614. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schneider B and Prvulovic D: Novel
biomarkers in major depression. Curr Opin Psychiatry. 26:47–53.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Conway CR, Gebara MA, Walker MC,
Lessov-Schlaggar CN, Janski AM, Chibnall JT, Cristancho P, Sheline
YI, Gott BM and Svrakic DM: Clinical characteristics and management
of treatment-resistant depression. J Clin Psychiatry. 76:1569–1570.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Juruena MF, Pariante CM, Papadopoulos AS,
Poon L, Lightman S and Cleare AJ: The role of mineralocorticoid
receptor function in treatment-resistant depression. J
Psychopharmacol. 27:1169–1179. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vandoolaeghe E, Maes M, Vandevyvere J and
Neels H: Hypothalamic-pituitary-thyroid-axis function in treatment
resistant depression. J Affect Disord. 43:143–150. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bodnar A, Krzywotulski M, Lewandowska A,
Chlopocka- Wozniak M, Bartkowska-Sniatkowska A, Michalak M and
Rybakowski JK: Electroconvulsive therapy and cognitive functions in
treatment-resistant depression. World J Biol Psychiatry.
17:159–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kiosses DN, Ravdin LD, Gross JJ, Raue P,
Kotbi N and Alexopoulos GS: Problem adaptation therapy for older
adults with major depression and cognitive impairment: A randomized
clinical trial. JAMA Psychiatry. 72:22–30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Y, Al-Sayegh H, Jabrah R, Wang W, Yan
F and Zhang J: Association between C-reactive protein and
depression: Modulated by gender and mediated by body weight.
Psychiatry Res. 219:103–108. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Matrisciano F, Bonaccorso S, Ricciardi A,
Scaccianoce S, Panaccione I, Wang L, Ruberto A, Tatarelli R,
Nicoletti F, Girardi P, et al: Changes in BDNF serum levels in
patients with major depression disorder (MDD) after 6 months
treatment with sertraline, escitalopram, or venlafaxine. J
Psychiatr Res. 43:247–254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Maes M: Evidence for an immune response in
major depression: A review and hypothesis. Prog
Neuropsychopharmacol Biol Psychiatry. 19:11–38. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dowlati Y, Herrmann N, Swardfager W, Liu
H, Sham L, Reim EK and Lanctôt KL: A meta-analysis of cytokines in
major depression. Biol Psychiatry. 67:446–457. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshimura R, Hori H, Ikenouchi-Sugita A,
Umene-Nakano W, Ueda N and Nakamura J: Higher plasma interleukin-6
(IL-6) level is associated with SSRI- or SNRI-refractory
depression. Prog Neuropsychopharmacol Biol Psychiatry. 33:722–726.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Krishnadas R and Cavanagh J: Depression:
An inflammatory illness? J Neurol Neurosurg Psychiatry. 83:495–502.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raison CL, Rutherford RE, Woolwine BJ,
Shuo C, Schettler P, Drake DF, Haroon E and Miller AH: A randomized
controlled trial of the tumor necrosis factor antagonist infliximab
for treatment-resistant depression: The role of baseline
inflammatory biomarkers. JAMA Psychiatry. 70:31–41. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wong ML, Dong C, Maestre-Mesa J and
Licinio J: Polymorphisms in inflammation-related genes are
associated with susceptibility to major depression and
antidepressant response. Mol Psychiatry. 13:800–812. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang C, Wu Z, Hong W, Wang Z, Peng D,
Chen J, Yuan C, Yu S, Xu L and Fang Y: Influence of BCL2 gene in
major depression susceptibility and antidepressant treatment
outcome. J Affect Disord. 155:288–294. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Stewart JC, Zielke DJ, Hawkins MA,
Williams DR, Carnethon MR, Knox SS and Matthews KA: Depressive
symptom clusters and 5-year incidence of coronary artery
calcification: The coronary artery risk development in young adults
study. Circulation. 126:410–417. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Michal M, Wiltink J, Kirschner Y, Wild PS,
Münzel T, Ojeda FM, Zeller T, Schnabel RB, Lackner K, Blettner M,
et al: Differential associations of depressive symptom dimensions
with cardio-vascular disease in the community: Results from the
Gutenberg health study. PLoS One. 8:e720142013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Deverts DJ, Cohen S, DiLillo VG, Lewis CE,
Kiefe C, Whooley M and Matthews KA: Depressive symptoms, race, and
circulating C-reactive protein: The Coronary Artery Risk
Development in Young Adults (CARDIA) study. Psychosom Med.
72:734–741. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Duivis HE, Vogelzangs N, Kupper N, de
Jonge P and Penninx BW: Differential association of somatic and
cognitive symptoms of depression and anxiety with inflammation:
Findings from the Netherlands Study of Depression and Anxiety
(NESDA). Psychoneuroendocrinology. 38:1573–1585. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chang HH, Wang TY, Lee IH, Lee SY, Chen
KC, Huang SY, Yang YK, Lu RB and Chen PS: C-reactive protein: A
differential biomarker for major depressive disorder and bipolar II
disorder. World J Biol Psychiatry. 18:63–70. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Köhler-Forsberg O, Buttenschøn HN, Tansey
KE, Maier W, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer
A, Rietschel M, et al: Association between C-reactive protein (CRP)
with depression symptom severity and specific depressive symptoms
in major depression. Brain Behav Immun. 62:344–350. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Uher R, Tansey KE, Dew T, Maier W, Mors O,
Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Farmer A, et al: An
inflammatory biomarker as a differential predictor of outcome of
depression treatment with escitalopram and nortriptyline. Am J
Psychiatry. 171:1278–1286. 2014. View Article : Google Scholar : PubMed/NCBI
|
